Shanghai, October 31, 2023 -- Luye Pharma Group today announced that its exclusive new drug, Rivastigmine Twice Weekly Transdermal Patch, has been approved by China's National Medical Products Adm...
Shanghai, October 9, 2023 - Luye Pharma Group today announced the submission of the New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) through the 505(b)(2) pathway for its LY03...
Luye Pharma Ltd, a subsidiary of Luye Pharma Group has launched an innovative new product for the treatment of Alzheimer's disease.Zeyzelf® twice weekly rivastigmine transdermal patch is for the s...
On September 7, 2023, Luye Life Sciences Group, in collaboration with the Ministry of Higher Education, Science, and Innovation of Uzbekistan, celebrated a signing ceremony in Tashkent for their joint...
Remarkable payoff for innovationStrong revenue growthAccelerated commercialization worldwideLuye Pharma Group (2186.HK) announced its 2023 half year results and recent developments on August 29, 2023....
Boan Biotech (6955.HK) announced its 2023 half year results and recent developments on August 27, 2023.Highlights of2023 half year resultsRobust revenue growthIn the first half of 2023, the company&rs...
August 1, 2023 – Luye Pharma Group today announced that the New Drug Application (NDA) of its weekly-dosed Rotigotine Extended-Release Microspheres for Injection (LY03003) for the treatment of P...
-Luye Pharma and BeiGene announce a strategic partnership for the commercialization of this product, the only one in the world--Providing a new ADT that is effective and safe with a better experience ...
Yantai, May 15, 2023– Boan Biotech today announced the completion of patient enrollment for the Phase III clinical trial (a comparative clinical study of efficacy and safety) of the company&rsqu...
- Company embarks on high-quality growth across the globe drivenby growing revenue and profit with the approval of several new drugs -Yantai, China, March 29, 2023 -Luye Pharma Group (2186.HK) today a...
TOP